Sulzer Medica bid to convert final opt-outs in US implants case
This article was originally published in Clinica
Executive Summary
Sulzer Medica last week found that it was not yet out of the woods in its efforts to settle US claims for compensation following problems with its hip and knee implants, when 120 plaintiffs refused to opt in for a share of the $1 billion compensation on offer from the Zurich, Switzerland company. 99.6% of plaintiffs opted for the package by the May 15 deadline, but the laggard 0.4% could present sizeable problems, and perhaps still force Sulzer's US orthopaedic subsidiary into bankruptcy.
You may also be interested in...
Investors Go Beserk For Viking, Putting It Top Of Q1 Winners
The top 10 biggest share price winners and losers in Q1 from Evaluate show the investor frenzy for obesity drugs continues, while companies with governance doubts see shareholders retreat.
EU Consults On What Constitutes Personal & Commercially Confidential Data In Marketing Applications
Based on their experience with dealing with requests for access to documents over the past 12 years, EU regulators have proposed updating their guideline that provides for a harmonized approach to protecting personal data and business secrets in marketing authorization applications.
Industry & Regulators To Align Advice on COVID-19 Vaccine Updates
A multi-stakeholder workshop looked at the data needed to support updates to vaccine composition and the time required by manufacturers to update their vaccines, change their manufacturing processes and prepare approval applications.